Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech, a member of the Roche Group, said that the review period for the supplemental biologics license applications (sBLAs) for Avastin (bevacizumab) has been extended by an additional 90 days, in accordance with the US Food and Drug Administration (FDA) guidelines.
Subscribe to our email newsletter
Genentech’s information submitted to the FDA during the review of the sBLAs for Avastin for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.
Genentech is expecting FDA action on the sBLAs by 17 December 2010.
Genentech stated that Avastin remains under accelerated approval, which was granted by the FDA in February 2008 for the drug in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer.
Genentech has submitted two sBLAs in November 2009 for Avastin in combination with taxane-based, anthracycline-based and capecitabine chemotherapies based on the results of the AVADO and RIBBON1 studies which are currently being reviewed by the FDA.
Genentech Product Development executive vice president and chief medical officer Hal Barron said that they were pleased by the FDA’s decision to review additional information on Avastin and are committed to working closely with the agency during this extended review period.